Wang I.-K.Yen T.-H.CHIH-HAO CHENHsu S.-P.Sun Y.Lien L.-M.Chang W.-L.Lai T.-C.Chen P.-L.Chen C.-C.Huang P.-H.Lin C.-H.Su Y.-C.Lin M.-C.Li C.-Y.Sung F.-C.Hsu C.Y.Taiwan Stroke Registry Investigators2022-03-082022-03-08202214602393https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123649413&doi=10.1093%2fqjmed%2fhcaa237&partnerID=40&md5=0dad4da7d6933f01ca9d07a4e33d53cbhttps://scholars.lib.ntu.edu.tw/handle/123456789/596700OBJECTIVE: This study used the Taiwan Stroke Registry data to evaluate the efficacy and safety of intravenous tissue plasminogen activator (tPA) in treating acute ischemic stroke in patients with renal dysfunction. DESIGN: We identified 3525 ischemic stro[SDGs]SDG3fibrinolytic agent; tissue plasminogen activator; brain ischemia; cerebrovascular accident; complication; fibrinolytic therapy; human; kidney disease; retrospective study; treatment outcome; Brain Ischemia; Fibrinolytic Agents; Humans; Ischemic Stroke; Kijournal article10.1093/qjmed/hcaa237327702522-s2.0-85123649413